The Interferons: Their Properties and Clinical Role — An Overview

  • Penella J. Woll
  • Derek Crowther
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

In 1957, two scientists working at the National Institute of Medical Research in London discovered that virus-infected cells became resistant to secondary infection. Drs. Alick Isaacs and Jean Lindenmann found that influenza virus-infected chick embryo cells released a substance that conferred on cells of the same species resistance to a wide range of viruses. This substance was named interferon and is now known to be secreted in small amounts by most vertebrate cells when they are appropriately stimulated. Interferon was originally described as a glycoprotein containing about 150 amino acids. It is now known that several types of interferon exist with differing amino-acid composition and varying amounts of carbohydrate.

Keywords

Cisplatinum Radium Oncol Doxorubicin Neutropenia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balkwill FR: Interferons. In: Cytokines in cancer therapy. Oxford University Press, Oxford 1989 pp8–53Google Scholar
  2. 2.
    Goodbourn S: The regulation of ß-interferon gene expression. Sem Cancer Biol 1990 (1): 89–95Google Scholar
  3. 3.
    Balkwill FR, Mowshowtitz S, Seilman SS, Moodie EM, Griffin, DB, Fantes KH and Wolf CR: Positive interactions between interferon and chemotherapy due to direct tumour action rather than effects on host drug-metabolising enzymes. Cancer Res 1984 (44): 5249–5255PubMedGoogle Scholar
  4. 4.
    Mehmet H, Taylor-Papadimitriou J and Rozengurt E: Interferon inhibition of bombesin-stimulated mitogenesis in Swiss 3T3 cells occurs without blocking c-fos and c-myc expression. J Interferon Res 1989 (9): 205–213PubMedCrossRefGoogle Scholar
  5. 5.
    Perez R, Lipton A, Harvey HA, Simmonds MA, Romano PJ, Imboden SL, Giudice G, Downing MR and Alton NK: A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy. J Biol Resp Mod 1988 (7): 309–317Google Scholar
  6. 6.
    Adams F, Quesada JR and Gutterman JU: Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J Am Med Ass 1984 (252): 938–941CrossRefGoogle Scholar
  7. 7.
    Merimsky O, Reider-Groswasser I, Inbar M and Chaichik S: Interferon-related mental deterioration and behavioural changes in patients with renal cell carcinoma. Eur J Cancer 1990 (26): 596–6007PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen MC, Huberman MS and Nesto RW: Recombinant alpha2 interferon-related cardiomyopathy. Am J Med 1988 (85): 549–551PubMedCrossRefGoogle Scholar
  9. 9.
    Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I and Bottazzo GF: An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988 (24): 1299–1303PubMedCrossRefGoogle Scholar
  10. 10.
    Golomb H, Fefer A, Golde D, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnem E, Spiegel R, Tensen L, Burke J and Vardiman JW: Update of a multi-institutional study of 195 patients (pts) with hairy cell leukaemia (HCL) treated with interferon-alfa2b (IFN). Proc Am Soc Clin Oncol 1990 (9): 215Google Scholar
  11. 11.
    Berman E, Heller G, Kempin S, Gee T, Tran LL and Clarkson B: Incidence of response and long term follow up in patients with hairy cell leukaemia treated with recombinant interferon alfa-2a. Blood 1990 (75): 839–845PubMedGoogle Scholar
  12. 12.
    Talpaz M, Kantarjian HM, Kurzrock R and Gutterman J: Therapy of chronic myelogenous leukaemia: chemotherapy and interferons. Sem Oncol 1988 (25): 62–73Google Scholar
  13. 13.
    Ozer H, Dear K, Testa J, Arthur D, Cooper R, Pettenati M, Ras K, Peterson BA, Schiffer C and Bloomfield CD: Prolonged administration of subcutaneous α interferon induces major clinical and complete cytogenetic remissions in untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML). Proc Am Soc Clin Oncol 1990 (9): 203Google Scholar
  14. 14.
    Catalano L, Majolino I, Musto P, Fragrasso A, Molica S, Cirincione S, Selleri C, Lucino L, DeRenzo A, Vecchione R and Rotoli B: Alpha interferon in the treatment of chronic myelomonocytic leukaemia. Haematologica 1989 (74): 577–581PubMedGoogle Scholar
  15. 15.
    Talpaz M, Kurzrock R, Kantarjian H, O’Brien S and Gutterman JU: Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 1989 (86): 554–558PubMedCrossRefGoogle Scholar
  16. 16.
    Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E and Radaszkiewicz T: Long term interferon therapy for thormbocytosis in myeloproliferative disease. Lancet 1989(1): 634–637PubMedCrossRefGoogle Scholar
  17. 17.
    Wagstaff J, Loynds P and Crowther D: A phase II study of human rDNA alpha-2 interferon in patients with low grade non Hodgkin’s lymphoma. Cancer Chemother Pharmacol 1985 (18): 54–58CrossRefGoogle Scholar
  18. 18.
    Tura S, Mazza P, Zinzani PL, Ghetti PL, Poletti G, Gherlionzoni F, Motgagnani A and Criscuolo D: Alpha recombinant interferon in the treatment of mycosis fungoides (MF). Haematologica 1987 (72): 337–340PubMedGoogle Scholar
  19. 19.
    Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N and Zeffren J: Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989 (20): 395–407PubMedCrossRefGoogle Scholar
  20. 20.
    Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA and Ihde DC: Phase II trial of intermittent high dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J Clin Oncol 1990 (8): 155–160PubMedGoogle Scholar
  21. 21.
    Braathen LR and McFadden N: Successful treatment of mycosis fungoides with the combination of etretinate and human recombinant interferon alfa-2a. J Dermatol. Treat 1989 (1): 29–32CrossRefGoogle Scholar
  22. 22.
    Rybak ME, McCarroll K, Bernard S, Lester E, Barcos M, Ozer H, Bloomfield CD and Gottleib AJ: Interferon therapy of relapsed and refractory Hodgkin’s disease: Cancer and Leukaemia Group B Study 8652. J Biol Resp Mod 1990 (9): 1–4.Google Scholar
  23. 23.
    Moertel CG, Rubib J and Kvols KL: Therapy of metastatic carcinoid syndrome with recombinant leucocyte A interferon. J Clin Oncol 1989 (7): 865–868PubMedGoogle Scholar
  24. 24.
    Öberg K, Norheim I and Aim G: Treatment of malignant carcinoid tumours: a randomised controlled study of streptozotocin plus 5-FU and human leucocyte interferon. Eur J Cancer Clin Oncol 1989 (25): 1475–1479PubMedCrossRefGoogle Scholar
  25. 25.
    Buzaid AC and Todd MB: Therapeutic options in renal cell carcinoma. Sem Oncol 1989 (16 suppl 1): 12–19Google Scholar
  26. 26.
    Legha SL: Current therapy for malignant melanoma. Sem Oncol 1989 (16 suppl 1): 34–44Google Scholar
  27. 27.
    Mattson K: Natural alpha interferon as part of a combined treatment for small cell lung cancer. In: Smyth JF (ed) Interferons in Oncology. European School of Oncology Monographs. Springer-Verlag, Berlin 1987 pp 25–32Google Scholar
  28. 28.
    Jett JR: Is there a role for interferon in the treatment of small cell lung cancer? Lung Cancer 1989 (5): 281–286CrossRefGoogle Scholar
  29. 29.
    White CW, Sondeheim HM, Crouch EC, Wilson H and Fan LL: Treatment of pulmonary haemangiomatosis with recombinant interferon alpha-2a. N Engl J Med 1989 (320): 1197–1200PubMedCrossRefGoogle Scholar
  30. 30.
    von Wussow P, Block B, Hartmann F and Deicher H: Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988 (61): 1071–1074CrossRefGoogle Scholar
  31. 31.
    Sulis E, Floris C, Sulis ML, Zurrida S, Piro S, Pintus A and Contu L: Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi’s sarcoma. Eur J Cancer Clin Oncol 1989 (25): 759–761PubMedCrossRefGoogle Scholar
  32. 32.
    Spirtos NM, Smith LH and Teng NM: Prospective randomised trial of topical alpha-interferon (alpha-interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecol Oncol 1990 (37): 34–38PubMedCrossRefGoogle Scholar
  33. 33.
    Rosso R, Rimoldi R, Salvatti F, De Palma M, Cinquegrana A, Nicolò G, Ardizzoni A, Fusco U, Cappaccio A, Centofanti R, Neri M, Cruciani AR and Maisto L: Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988 (45): 253–256PubMedCrossRefGoogle Scholar
  34. 34.
    Berek JS, Hacker, NF, Lichenstein A, Jung T, Spina C, Knox, RM, Brady J, Greene T, Ettinger LM and Lagasse LD: Intraperitoneal recombinant alpha-Interferon for salvage immunotherapy in stage III epithelial ovarian cancer. A Gynecologic Oncology Group study. Cancer Res 1985 (45): 4447–4453PubMedGoogle Scholar
  35. 35.
    Welander CE: Interferon in the treatment of ovarian cancer. Sem Oncol 1988 (15, suppl. 5): 26–29Google Scholar
  36. 36.
    Pujade-Lauraine E, Colombo N, Namer N, Fumoleau P, Monnier A, Nooy MA, Falkson G, Mignot L, Bugat R, Oliveira CMD, Mousseau M, Netter ZG, Oberling F, Coiffier B and Brandley M: Intraperitoneal human rIFN gamma in patients with residual ovarian carcinoma at second look laparotomy. Proc Am Soc Clin Oncol 1990 (9): 156Google Scholar
  37. 37.
    Lum BL and Torti FM: Therapeutic approaches including interferon to carcinoma in situ of the bladder. Cancer Treat Rev 1985 (12, suppl B): 45–59PubMedGoogle Scholar
  38. 38.
    Ackerman, D, Biedermann C, Bailly G, Studer UE: Treatment of superficial bladder tumour with intravesical recombinant interferon-α2a. Urol Int 1988 (43): 85–88CrossRefGoogle Scholar
  39. 39.
    Chodak GW: Intravesical interferon treatment of superficial bladder cancer. Urology 1989 (34, suppl 4): 84–86PubMedCrossRefGoogle Scholar
  40. 40.
    Kinnula V, Cantell K and Mattson K: Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma. Eur J Cancer 1990 (26): 740–741PubMedCrossRefGoogle Scholar
  41. 41.
    van Zandwijk N, Jassem E, Dubbelmann R, Braat MCP and Rumke P: Aerosol application of interferon-alpha in the treatment of bronchioalveolar carcinoma. Eur J Cancer 1990 (26): 738–740PubMedCrossRefGoogle Scholar
  42. 42.
    Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp, C, Calabro S, Karp SE, Sherry RM, Stenberg S and White DE: Combination therapy with interleukin-2 and alfa interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989 (7): 1863–1874PubMedGoogle Scholar
  43. 43.
    Atzpodien J, Korfer A, Franks CR, Poliwoda H and Kirchner H: Home therapy with recombinant interleukin 2 and interferon α-2b in advanced human malignancies. Lancet 1990 (335): 1509–1512PubMedCrossRefGoogle Scholar
  44. 44.
    Wadler S and Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990 (50): 3473–3486PubMedGoogle Scholar
  45. 45.
    Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V and Wiernik PH: Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1988 (7): 1769–1775Google Scholar
  46. 46.
    Wadler S and Wiernik PH: Clinical update on the role of fluorouracil and recombinant interferon alpha-2b in the treatment of colorectal carcinoma. Sem Oncol 1990(17, suppl 1): 16–21Google Scholar
  47. 47.
    Balkwill FR: Peptide regulatory factors. Interferons. Lancet 1989 (1): 1060–1063PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Penella J. Woll
    • 1
  • Derek Crowther
    • 1
  1. 1.CRC Department of Medical OncologyChristie Hospital and Holt Radium InstituteManchesterUK

Personalised recommendations